NASDAQ · Medical - Devices

Vivos Therapeutics, Inc. (VVOS) Stock

$0.39 -0.81% NASDAQ: VVOS Healthcare

Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults.

Valuation

MetricValue
Price$0.39
Market Cap$2.30M
P/E Ratio-0.17
P/B Ratio-5.06
P/S Ratio0.12
EPS (TTM)$-0.35
52-Week High$5.69
52-Week Low$0.36
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-1599.81%
ROA-100.30%
ROCE-317.98%
Gross Margin59.48%
Operating Margin-1.15%
Net Margin-128.36%
Debt/Equity-10.78
Current Ratio0.22

Annual Financials (USD)

Metric20212022202320242025
Revenue$17.0M$16.0M$14.0M$15.0M$17.0M
Operating Profit$-19.0M$-25.0M$-17.0M$-11.0M$-20.0M
Net Profit$-20.0M$-24.0M$-14.0M$-11.0M$-21.0M
EPS$-23.89$-25.90$-11.14$-2.22$-2.06
Op Margin-115.3%-156.2%-125.3%-74.3%-114.0%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$34.0M$14.0M$11.0M$15.0M$25.0M
Total Liabilities$8.0M$9.0M$10.0M$7.0M$27.0M
Cash$24.0M$4.0M$2.0M$6.0M$2.0M
Borrowings$2.0M$2.0M$2.0M$2.0M$14.0M

Latest News

Vivos Therapeutics (VVOS) Stock Fair Value Falls After Analyst Target Cuts Simply Wall St. · Jul 18, 2026 Vivos Therapeutics (VVOS) Stock Sees Fair Value Moves Lower As Analysts Reset Growth Assumptions Simply Wall St. · Jul 3, 2026 Vivos’ Vida® Appliance Shows Statistically Significant Improvement in Insomnia Severity in 100% of Study Participants GlobeNewswire · Jun 30, 2026 Sector Update: Healthcare Stocks Rise Late Afternoon MT Newswires · Jun 22, 2026 Vivos Therapeutics Extends Financing Agreement With Streeterville Through August MT Newswires · Jun 22, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-16.0M$-20.0M$-12.0M$-13.0M$-15.0M
Investing Cash Flow$-5.0M$-2.0M$-2.0M$-1.0M$-10.0M
Financing Cash Flow$-1.0M$0$0$10.0M$0
Net Cash Flow$6.0M$-21.0M$-2.0M$5.0M$-4.0M
Free Cash Flow$-18.0M$-21.0M$-13.0M$-13.0M$-18.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.01
EV / EBITDA-0.53
FCF Yield-783.86%
Quick Ratio0.22
Interest Coverage0.00
Return 1Y-93.87%
Return 3Y-94.79%
Return 5Y-99.59%

Ownership

Insiders Held26.35%
Institutions Held13.47%
Institutions Float Held18.29%
Institutional HolderSharesReport Date
Armistice Capital, LLC1,115,8592026-03-31
Vanguard Capital Management LLC273,3292026-03-31
Geode Capital Management, LLC95,5432026-03-31
Commonwealth Equity Services, LLC42,5002026-03-31
IHT Wealth Management, LLC41,0612026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ADGM $0.38 +1.60% -0.56 $8.45M 0.00%
AEMD $0.57 +6.51% -0.02 $430885 0.00%
ALURAllurion Technologies Inc. $4.72 -14.27% -0.08 $4.72M 0.00%
AMS $1.51 +3.42% -6.17 $10.00M 0.00%
ANLAdlai Nortye Ltd. $13.26 +2.00% -8.19 $703.84M 0.00%

About Vivos Therapeutics, Inc.

Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was formerly known as Vivos BioTechnologies, Inc. and changed its name to Vivos Therapeutics, Inc. in March 2018. The company was founded in 2016 and is based in Littleton, Colorado.

Vivos Therapeutics, Inc. is led by CEO R. Kirk Huntsman, employs 109 people, headquartered in US, publicly traded since 2020.

Vivos Therapeutics, Inc. (VVOS) stock trades at $0.39 with a market capitalization of $2.30M. The stock is valued at a price-to-earnings (P/E) ratio of -0.17, price-to-book of -5.06, price-to-sales of 0.12. Over the past 52 weeks the stock has ranged between $0.36 and $5.69, and currently trades 93.1% below its 52-week high.

On profitability, Vivos Therapeutics, Inc. generates a return on equity (ROE) of -1599.81%, return on capital employed of -317.98%, an operating margin of -1.15%, a net profit margin of -128.36%.

Official website: www.vivos.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides